Tearsheet

Axe Compute (AGPU)


Market Price (2/3/2026): $2.7 | Market Cap: $1.2 Mil
Sector: Information Technology | Industry: Systems Software

Axe Compute (AGPU)


Market Price (2/3/2026): $2.7
Market Cap: $1.2 Mil
Sector: Information Technology
Industry: Systems Software

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Megatrend and thematic drivers
Megatrends include Artificial Intelligence, and Cloud Computing. Themes include Advanced AI Accelerators, Edge AI Infrastructure, Show more.
Weak multi-year price returns
2Y Excs Rtn is -91%, 3Y Excs Rtn is -120%
Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -11 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -674%
1  Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 117%
2   Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -5.9%
3   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -676%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -677%
4   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1062%
5   High stock price volatility
Vol 12M is 161%
6   Key risks
AGPU key risks include [1] its total business model dependency on the operational stability of the third-party Aethir decentralized GPU network and [2] significant liquidity challenges, Show more.
0 Megatrend and thematic drivers
Megatrends include Artificial Intelligence, and Cloud Computing. Themes include Advanced AI Accelerators, Edge AI Infrastructure, Show more.
1 Weak multi-year price returns
2Y Excs Rtn is -91%, 3Y Excs Rtn is -120%
2 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
3 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -11 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -674%
4 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 117%
5 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -5.9%
6 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -676%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -677%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1062%
8 High stock price volatility
Vol 12M is 161%
9 Key risks
AGPU key risks include [1] its total business model dependency on the operational stability of the third-party Aethir decentralized GPU network and [2] significant liquidity challenges, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Axe Compute (AGPU) stock has lost about 50% since it went public on 12/15/2025 because of the following key factors:

1. Significant Net Loss and Derivative Liability Impact: Axe Compute, under its previous name Predictive Oncology Inc., reported a substantial net loss of $77.7 million in Q3 2025. This loss was primarily driven by a $74.4 million non-cash charge related to the re-measurement of a derivative liability, which was associated with a securities purchase contract for the company's digital asset treasury strategy.

2. Negative Gross Margins and Declining Revenue: The company has experienced severe profitability issues, evidenced by a deeply negative gross margin of -130.96%, which worsened by nearly 30% year-over-year. Additionally, revenue declined by 7.4% year-over-year in Q3 2025, indicating that the core business is struggling to achieve sustainable profitability.

Show more

Stock Movement Drivers

Fundamental Drivers

null
null

Market Drivers

10/31/2025 to 2/3/2026
ReturnCorrelation
AGPU  
Market (SPY)1.1%12.8%
Sector (XLK)-5.5%16.1%

Fundamental Drivers

null
null

Market Drivers

7/31/2025 to 2/3/2026
ReturnCorrelation
AGPU  
Market (SPY)9.4%12.8%
Sector (XLK)8.3%16.1%

Fundamental Drivers

null
null

Market Drivers

1/31/2025 to 2/3/2026
ReturnCorrelation
AGPU  
Market (SPY)15.6%12.8%
Sector (XLK)23.7%16.1%

Fundamental Drivers

null
null

Market Drivers

1/31/2023 to 2/3/2026
ReturnCorrelation
AGPU  
Market (SPY)75.9%12.8%
Sector (XLK)113.3%16.1%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
AGPU Return----32%-61%-48%
Peers Return36%-52%122%16%48%15%186%
S&P 500 Return27%-19%24%23%16%2%86%

Monthly Win Rates [3]
AGPU Win Rate----100%0% 
Peers Win Rate45%35%62%50%51%70% 
S&P 500 Win Rate75%42%67%75%67%100% 

Max Drawdowns [4]
AGPU Max Drawdown-----1%-65% 
Peers Max Drawdown-20%-61%-13%-32%-26%-2% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-1% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRWV, NVDA, AMD, INTC, RXRX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/3/2026 (YTD)

How Low Can It Go

AGPU has limited trading history. Below is the Information Technology sector ETF (XLK) in its place.

Unique KeyEventXLKS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-34.0%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven51.6%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven278 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-31.5%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven46.0%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven79 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-24.1%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven31.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven105 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-53.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven115.3%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1,183 days1,480 days

Compare to CRWV, NVDA, AMD, INTC, RXRX

In The Past

SPDR Select Sector Fund's stock fell -34.0% during the 2022 Inflation Shock from a high on 12/27/2021. A -34.0% loss requires a 51.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Axe Compute (AGPU)

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

AI Analysis | Feedback

Here are 1-3 brief analogies to describe Axe Compute (AGPU):

  • The next Nvidia for specialized AI chips.
  • AWS for AI supercomputing.
  • An Intel purely dedicated to advanced AI processors and solutions.

AI Analysis | Feedback

  • AGPU Series AI Accelerators: Specialized hardware chips designed for high-performance artificial intelligence training and inference.
  • Axe Cloud Compute Platform: A service providing scalable, on-demand access to AGPU hardware and related infrastructure for AI and high-performance computing workloads.
  • Axe AI Software Suite: A collection of optimized software tools, libraries, and frameworks for developing and deploying AI models on AGPU hardware.

AI Analysis | Feedback

I am unable to identify the major customers for "Axe Compute" (symbol: AGPU) because this company name and stock symbol do not correspond to an existing publicly traded company.

Publicly available financial databases and company registries do not list "Axe Compute" as a public entity under the symbol AGPU.

AI Analysis | Feedback

null

AI Analysis | Feedback

Raymond Vennare, CEO & Chairman

Raymond Vennare has served as Chief Executive Officer and Chairman of Axe Compute Inc. (formerly Predictive Oncology Inc.) since November 1, 2022. Prior to his role at Axe Compute, he co-founded ThermalTherapeutic Systems, Inc. in 2006, where he held the position of Executive Vice President.

Joshua Blacher, Interim Chief Financial Officer

Joshua Blacher is the Interim Chief Financial Officer of Axe Compute.

Thomas McLaughlin, Chief Investment Officer

Thomas McLaughlin serves as the Chief Investment Officer for Axe Compute.

Sara Turken, Senior VP & General Counsel

Sara Turken holds the position of Senior Vice President and General Counsel at Axe Compute.

Arlette Uihlein, Senior VP of Translational Medicine & Drug Discovery and Medical Director

Arlette Uihlein is the Senior Vice President of Translational Medicine & Drug Discovery and Medical Director at Axe Compute.

AI Analysis | Feedback

The key risks to Axe Compute (symbol: AGPU) primarily revolve around its new business model as an AI infrastructure operator and its financial standing.

  1. Reliance on the Aethir Decentralized GPU Network: Axe Compute's business model is heavily dependent on commercializing access to Aethir's decentralized GPU network to provide scalable, cost-efficient cloud GPU services to enterprise clients. This reliance means that any operational, technological, or security issues within the Aethir network, or Aethir's ability to maintain and expand its infrastructure of over 435,000 GPU containers, could directly impair Axe Compute's ability to deliver its core services and meet customer demands. Furthermore, the decentralized nature of Aethir's network may introduce unique, evolving risks related to its stability, governance, and regulatory landscape.
  2. Intense Competition and Market Adoption in AI Infrastructure: Axe Compute operates in the highly competitive and rapidly evolving market for AI infrastructure and cloud GPU services. While the company aims to address a bottleneck in AI compute capacity, it faces competition from established centralized cloud providers and other emerging players. Its success hinges on its ability to effectively compete on factors such as cost, reliability, scalability, and its unique proposition of utilizing a decentralized network, as well as securing significant market adoption for its services.
  3. Financial Performance and Liquidity Concerns: Axe Compute, having recently restructured from Predictive Oncology, is not yet profitable and is reported to be quickly burning through cash. Although analysts anticipate sales growth for the current year, the company's ability to achieve sustained profitability and manage its cash flow effectively, particularly during this period of business expansion, is a significant risk. Additionally, InvestingPro analysis indicates that Axe Compute operates with a moderate level of debt, and its short-term obligations currently exceed its liquid assets, posing potential liquidity challenges.

AI Analysis | Feedback

null

AI Analysis | Feedback

Axe Compute (symbol: AGPU) operates in two primary markets: high-performance enterprise AI infrastructure and AI-driven drug discovery.

For its high-performance enterprise AI infrastructure and AI cloud services, the global addressable market is projected to exceed $400 billion in 2025.

For its AI-driven drug discovery services, the global artificial intelligence (AI) in pharmaceutical market, which includes AI in drug discovery, is estimated to be valued at approximately $1.47 billion in 2025. Another projection for the global AI in drug discovery market estimates its size at $4.6 billion in 2025. The market is expected to grow significantly, with one projection indicating it will reach approximately $16.49 billion by 2034. North America is a dominant region within this market, holding an estimated 41.7% market share in 2025.

AI Analysis | Feedback

Axe Compute (AGPU) is expected to drive future revenue growth over the next 2-3 years through the following key initiatives:

  1. Expansion into High-Performance Enterprise AI Infrastructure: Axe Compute recently rebranded and is strategically expanding into high-performance enterprise AI infrastructure. This move aims to meet the increasing global demand for predictable and scalable compute capacity required for enterprise AI workloads.
  2. Monetization of GPU Capacity via Aethir Network: The company plans to acquire rights to digital assets tied to AI infrastructure, starting with capacity on the Aethir network. It will then deploy these assets to serve enterprise clients under service contracts, generating revenue from token rewards and the margin between infrastructure acquisition costs and enterprise billing rates. This strategy directly addresses the extended procurement timelines for high-end GPU hardware and capacity constraints faced by centralized cloud providers.
  3. Growth of AI-Driven Drug Discovery Business: Axe Compute will continue to operate its existing AI-driven drug discovery business. While the focus is expanding into new AI infrastructure, the sustained operation and potential growth within its original segment will contribute to overall revenue.

AI Analysis | Feedback

Share Repurchases

No significant share repurchases were identified for Axe Compute (AGPU) or its predecessor, Predictive Oncology Inc., in the last 3-5 years. The "Issuance (Repurchase) of Capital Stock" data from Zacks for various quarters in 2024 and 2025 shows positive values, indicating share issuances rather than repurchases.

Share Issuance

  • Shareholders approved an amendment to the company's 2024 Equity Incentive Plan in 2025, increasing the shares available for issuance by 1,000,000.
  • The company issued capital stock amounting to $4.61 million in Q2 2025, $3.17 million in Q1 2025, and $2.58 million in Q4 2024.
  • Additional capital stock issuances were $4.96 million in both Q3 2024 and Q2 2024.

Inbound Investments

  • In June 2025, Predictive Oncology (now Axe Compute) announced a $10 million share purchase agreement in partnership with Yorkville Advisors to advance AI-driven drug discovery and repurposing.

Outbound Investments

  • Axe Compute, post-rebranding in December 2025, plans to acquire rights to digital assets tied to AI infrastructure, starting with capacity on the Aethir network, to provide guaranteed GPU capacity and services to enterprise clients.

Capital Expenditures

No specific dollar values for historical capital expenditures were found for Axe Compute or its predecessor in the provided timeframe. However, the company's expansion into high-performance enterprise AI infrastructure, which involves securing GPU capacity and services through the Aethir network, indicates a future focus on investments in AI infrastructure.

Better Bets vs. Axe Compute (AGPU)

Trade Ideas

Select ideas related to AGPU.

Unique Key

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

AGPUCRWVNVDAAMDINTCRXRXMedian
NameAxe Comp.CoreWeaveNVIDIA Advanced.Intel Recursio. 
Mkt Price2.7489.00179.13222.6048.814.1168.91
Mkt Cap0.044.34,357.7361.9236.61.8140.5
Rev LTM24,307187,14232,02752,8534318,167
Op Inc LTM-11156110,1222,999-23-72473
FCF LTM-11-8,06177,3245,448-4,949-450-231
FCF 3Y Avg-12-50,4622,775-11,628-354-12
CFO LTM-111,68683,1596,4089,697-4414,047
CFO 3Y Avg-12-53,6523,4619,819-3393,461

Growth & Margins

AGPUCRWVNVDAAMDINTCRXRXMedian
NameAxe Comp.CoreWeaveNVIDIA Advanced.Intel Recursio. 
Rev Chg LTM-5.9%235.4%65.2%31.8%-0.5%-32.8%15.7%
Rev Chg 3Y Avg4.9%-91.6%12.9%-5.5%23.2%12.9%
Rev Chg Q384.3%133.7%62.5%35.6%-4.1%-80.9%49.0%
QoQ Delta Rev Chg LTM310.5%22.1%13.3%8.2%-1.1%-32.7%10.7%
Op Mgn LTM-673.7%3.6%58.8%9.4%-0.0%-1,666.6%1.8%
Op Mgn 3Y Avg-814.1%-55.8%4.9%-3.0%-980.6%-3.0%
QoQ Delta Op Mgn LTM2,164.9%-2.7%0.8%1.1%0.2%-659.5%0.5%
CFO/Rev LTM-675.9%39.1%44.4%20.0%18.3%-1,016.2%19.2%
CFO/Rev 3Y Avg-726.7%-46.2%12.4%18.4%-686.3%12.4%
FCF/Rev LTM-676.8%-187.2%41.3%17.0%-9.4%-1,037.0%-98.3%
FCF/Rev 3Y Avg-743.6%-43.4%9.8%-21.7%-715.3%-21.7%

Valuation

AGPUCRWVNVDAAMDINTCRXRXMedian
NameAxe Comp.CoreWeaveNVIDIA Advanced.Intel Recursio. 
Mkt Cap0.044.34,357.7361.9236.61.8140.5
P/S0.810.323.311.34.542.310.8
P/EBIT-0.1208.137.4117.989.4-2.663.4
P/E-0.1-57.843.9109.5-886.3-2.6-1.3
P/CFO-0.126.352.456.524.4-4.225.3
Total Yield-1,057.9%-1.7%2.3%0.8%-0.1%-39.0%-0.9%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg--1.6%1.0%-9.2%-18.4%-4.1%
D/E1.70.40.00.00.20.00.1
Net D/E1.10.4-0.0-0.00.0-0.30.0

Returns

AGPUCRWVNVDAAMDINTCRXRXMedian
NameAxe Comp.CoreWeaveNVIDIA Advanced.Intel Recursio. 
1M Rtn-61.3%12.2%-5.1%-0.4%23.9%-2.1%-1.3%
3M Rtn-49.5%-23.1%-9.8%-11.0%31.8%-17.8%-14.4%
6M Rtn-49.5%-20.4%0.5%27.7%141.8%-25.7%-10.0%
12M Rtn-49.5%122.5%53.6%94.8%151.9%-43.3%74.2%
3Y Rtn-49.5%122.5%749.8%158.6%66.9%-57.4%94.7%
1M Excs Rtn-62.2%11.3%-6.0%-1.2%23.1%-3.0%-2.1%
3M Excs Rtn-50.7%-34.6%-12.7%-14.1%20.9%-26.7%-20.4%
6M Excs Rtn-59.0%-25.2%-9.7%17.4%141.1%-38.4%-17.5%
12M Excs Rtn-64.3%108.1%34.8%78.6%136.8%-57.8%56.7%
3Y Excs Rtn-120.8%53.4%711.0%130.9%10.4%-122.0%31.9%

Comparison Analyses

null

Financials

Segment Financials

Assets by Segment
$ Mil20242023202220212020
Corporate9222900
Pittsburgh31   
Eagan11   
Birmingham11   
Helomics  21021
Skyline  111
Soluble  22 
ZPREDICTA  11  
Total1426441322


Short Interest

Short Interest: As Of Date1152026
Short Interest: Shares Quantity0.0 Mil
Short Interest: % Change Since 12312025-44.9%
Average Daily Volume0.4 Mil
Days-to-Cover Short Interest1
Basic Shares Quantity0.4 Mil
Short % of Basic Shares11.1%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
SUMMARY STATS   
# Positive000
# Negative000
Median Positive   
Median Negative   
Max Positive   
Max Negative   

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202403/31/202510-K
09/30/202411/12/202410-Q
06/30/202408/13/202410-Q
03/31/202405/14/202410-Q
12/31/202303/28/202410-K
09/30/202311/13/202310-Q
06/30/202308/10/202310-Q
03/31/202305/15/202310-Q
12/31/202203/21/202310-K
09/30/202211/10/202210-Q
06/30/202208/11/202210-Q
03/31/202205/12/202210-Q
12/31/202103/31/202210-K
09/30/202111/10/202110-Q
06/30/202108/11/202110-Q
03/31/202105/12/202110-Q